Autopsy report · NCT03917381
GEN1046 Safety Trial in Patients With Malignant Solid Tumors
Cause of deathFunding or business
“Genmab has decided to discontinue further clinical development of acasunlimab following strategic portfolio prioritization. The decision was not related to safety concerns.”
Life of this trial
- Registered 1 month before it started.
- Ran for about 7 years 3 months before it stopped.
- 429 participants enrolled.
- Results were posted on the registry 0 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1, Phase 2
- Sponsor
- Genmab
- Sponsor type
- Industry
- Conditions
- Solid Tumors
- Interventions
- Acasunlimab; Acasunlimab in combination with docetaxel (in a single expansion cohort); Acasunlimab in combination with pembrolizumab (in a separate expansion cohort); Acasunlimab in combination with pembrolizumab and standard chemotherapy (in separate expansion cohorts)
- Participants
- 429
- Sites
- 57
- Countries
- Czechia, Georgia, Hungary, Israel, Italy, Poland, Spain, Turkey (Türkiye), Ukraine, United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.